



## Review

**Cite this article:** Sheng M, Ertürk A. 2014  
Long-term depression: a cell biological view.  
*Phil. Trans. R. Soc. B* **369**: 20130138.  
<http://dx.doi.org/10.1098/rstb.2013.0138>

One contribution of 35 to a Discussion Meeting  
Issue 'Synaptic plasticity in health and disease'.

### Subject Areas:

neuroscience, cellular biology

### Keywords:

long-term potentiation, dendritic spine, local  
apoptosis, caspase, long-term depression,  
spine elimination

### Author for correspondence:

Morgan Sheng  
e-mail: [sheng.morgan@gene.com](mailto:sheng.morgan@gene.com)

# Long-term depression: a cell biological view

Morgan Sheng and Ali Ertürk

Department of Neuroscience, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Recent studies of the molecular mechanisms of long-term depression (LTD) suggest a crucial role for the signalling pathways of apoptosis (programmed cell death) in the weakening and elimination of synapses and dendritic spines. With this backdrop, we suggest that LTD can be considered as the electrophysiological aspect of a larger cell biological programme of synapse involution, which uses localized apoptotic mechanisms to sculpt synapses and circuits without causing cell death.

## 1. Introduction


Long-term potentiation (LTP) and long-term depression (LTD) are much studied for their own sake as fascinating neurophysiological phenomena as well as for their crucial relevance for brain development, cognitive function and human nervous system diseases. Numerous excellent and worthy reviews have been written about the mechanisms of LTP and/or LTD, but mostly from a physiological–pharmacological and/or molecular perspective [1–6]. The majority of these reviews tend to portray synapses as largely conceptual compartments in which signalling pathways (kinases, phosphatases, etc.) are activated or inactivated, resulting in changes in the function and abundance of postsynaptic glutamate receptors. The dynamic aspects of synaptic plasticity mechanisms—such as the synaptic delivery of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in LTP and the removal/endocytosis of AMPA receptors in LTD, which are now widely accepted in the field [1,7–9]—are often conceptually divorced from the structural and cell biological changes taking place in the neuron and synapse as a whole. In this review, we offer a view of LTD from a cell biologist's perspective, emphasizing the idea that weakening of synaptic transmission and endocytosis of AMPA receptors occur not in molecular isolation, but rather in the context of an 'involution' of synapses, whereby synapses wither and die and their contents are mobilized and removed.

## 2. Caspases and apoptotic mechanisms in long-term depression

Programmed cell death (also called apoptosis) [10] removes excess cells that form during the development of an organism, sculpting a wide range of tissues and organs, not least the nervous system, into their adult form [11,12]. The process of apoptosis—which involves the coordinated regulation and action of multiple genes and proteins—results in the timely demise and tidy removal of unwanted cells with minimal inflammatory or other untoward effects on surrounding tissues. In recent years, evidence is accumulating for an involvement of the molecular mechanisms of apoptosis in processes that do not result in cell death (i.e. non-apoptotic pathways).

Examples of non-cell death roles of apoptotic mechanisms in the nervous system include the dendritic pruning of *Drosophila* neurons during development [13,14], the structural remodelling of hippocampal neuron synapses and *Xenopus* retinal growth cones [15,16], and bird song learning [17]. This topic has been reviewed recently by Hyman & Yuan [18].

The cysteine-aspartate protease caspase-3 is well established as a key 'executioner' enzyme in the programmed cell death of neurons and other cell types



**Figure 1.** A putative illustration of apoptotic pathway involvement in spine pruning. LTD induces  $\text{Ca}^{2+}$  influx via NMDA receptors and an increase in  $\text{Ca}^{2+}$  levels in mitochondria, which leads to cytochrome *c* release. Activation of the mitochondrial apoptosis pathway culminates in activation of caspase-3, which exerts local effects on synaptic strength (LTD) and spine size by proteolysis of proteins in the postsynaptic compartment, e.g. Akt. The ubiquitin-proteasome system (UPS) and IAPs inhibit activated caspases and limit the extent of local synaptic apoptosis. For simplicity, NMDA receptors are shown only in one spine at bottom of the dendrite, and the LTD effects of AMPA receptor depletion and spine shrinkage are shown only on the upper side of the dendrite (GSK3 $\beta$ , glycogen synthase kinase-3 $\beta$ ).

[11]. Caspase-3 (and its close relative caspase-7) lies downstream of the two major apoptotic pathways—intrinsic and extrinsic—within cells. In the intrinsic (or mitochondrial) pathway, apoptotic stimuli lead to release of proapoptotic molecules, such as cytochrome *c* and second mitochondria-derived activator of caspases (SMAC, also known as DIABLO), from mitochondria; these molecules lead to activation of caspase-9, which then cleaves and activates caspase-3 and caspase-7, leading to apoptosis [19]. The release of cytochrome *c* from mitochondria is inhibited by antiapoptotic members of the Bcl-2 family of proteins (such as Bcl-xL) and promoted by proapoptotic members (such as BAD, BAX and BAK) [20]. In the cytoplasm, activation of the caspase-9–caspase-3 cascade is restrained by inhibitor of apoptosis proteins (IAPs) which bind to and inhibit these caspases [21,22].

In addition to their crucial role in programmed cell death, recent studies show that apoptotic mechanisms, in particular caspase-3, participate in LTD and perhaps synapse elimination in the absence of cell death. Pharmacologic inhibition of caspase-3/7 or genetic disruption of caspase-3 in mice blocks induction of LTD in CA1 region of hippocampus [23]. *N*-methyl-D-aspartate (NMDA) receptor-dependent AMPA receptor internalization—which is an essential mechanism underlying LTD induction—is also blocked by the same manipulations in cultured neurons [23]. Thus, caspase-3 activity is required for NMDA receptor-dependent LTD. Interestingly, caspase-3 does not appear to be necessary for mGluR-dependent LTD (Kei Cho 2013, personal communication, [24]). In addition, knockout mice lacking BAD or BAX (proapoptotic Bcl-2 family proteins) are defective in AMPA receptor internalization and NMDA receptor-

dependent LTD, but not in mGluR-dependent LTD [24]. In hippocampal slice cultures, postsynaptic overexpression of Bcl-xL (an antiapoptotic Bcl-2 family member) suppresses the induction of LTD [23]. Together, these data strongly support the idea that activation of the mitochondrial (intrinsic) pathway of apoptosis—which seems to occur at least in part within the postsynaptic compartment—is required for LTD. LTD in hippocampal slice cultures is also inhibited by postsynaptic overexpression of different fragments of XIAP (an IAP protein that inhibits caspase-9 and caspase-3), confirming the importance of caspase-9–caspase-3 activity in LTD [23].

### 3. Localized ‘synaptic apoptosis’ as a conceptual framework for long-term depression

Caspase-3 is necessary for LTD, but is it activated during LTD? This has been more difficult to ascertain, because the degree and extent of caspase-3 activation would be predicted to be less than that occurring during programmed cell death. Indeed, by staining and immunoblotting approaches, it has been shown that caspase-3 is activated, but only to a modest extent, following bath NMDA stimulation (‘chemical LTD’) [23,24]. Active caspase-3 was detectable in dendrites as well as cell body under such conditions [23].

The activation of caspase-3 (and presumably the mitochondrial apoptosis pathway leading to caspase-3 activation) may be restricted to peripheral compartments of the neuron so that death of the entire cell does not ensue (figure 1). This has given rise to the idea of localized ‘synaptic apoptosis’—a term first coined by Mattson *et al.* [25]—as the cell biological basis of LTD. A critical question that remains is whether local activation


of the mitochondrial apoptosis pathway and of caspase-3 is *sufficient*—as opposed to just being *necessary*—for LTD. Addressing this question will require development of experimental tools to activate apoptosis mechanisms within neurons at a specific location and time. An important related unknown is the molecular mechanism(s) by which active caspase-3 contributes to LTD.

Once apoptotic mechanisms including caspase-3 are locally activated by LTD-inducing stimuli, what determines the outcome between local synapse weakening versus cell-wide death? It appears that the mitochondrial apoptotic pathway is only transiently and modestly activated by LTD-inducing stimulation, whereas neuronal cell death is associated with higher levels of activation of apoptotic mechanisms and caspases [23,24,26]. We hypothesize that a greater amplitude, broader extent and/or longer duration of activation of the mitochondria-caspase pathway in neurons would be required to mediate cell death. It is possible that the dendrites of a neuron might be able to integrate depressive signals, such that only when these signals accumulate beyond a certain threshold, do they lead to apoptotic death of the whole neuron. When the apoptotic signals are below the threshold for cell death, only local synaptic apoptosis can occur. The elaborate, extended morphology of neurons is well suited for localized apoptosis to occur in restricted compartments far from the cell body. The mechanisms that ‘insulate’ the effects of apoptosis to localized peripheral regions of the cell are presently unclear but would be important to study. It would not be surprising if there were active cell biological mechanisms to restrict the spread of local synaptic apoptosis in neurons, just as there are active mechanisms to inhibit the progression of apoptotic cell death [20].

How big is the region of localized synaptic apoptosis? Most dendritic mitochondria are quite large relative to individual spines (typically 2–20  $\mu\text{m}$  in length [27]). Mitochondria reside within the dendrite shaft and they span lengths that encompass multiple spines/synapses (figure 2). If the mitochondrial release of proapoptotic factors, and consequent activation of the caspase-9–caspase-3 cascade, mediates the induction of LTD, one would expect that LTD would spread over considerably more than 10  $\mu\text{m}$ . Previous conclusions of the homosynaptic nature of LTD are largely based on experiments showing pathway or input specificity, in which the stimulated pathways/inputs could be hundreds of micrometres apart. In such circumstances, short-distance heterosynaptic LTD could be missed. Indeed, LTD has been reported to ‘spread’ more than LTP [28], and heterosynaptic LTD (LTD occurring at unstimulated synapses) has been described in several studies [29,30].

#### 4. Localized apoptosis and ‘synapse involution’

Interestingly, LTD is most robustly inducible during the period of two to four weeks of age in a rodent’s life [31,32], which corresponds to the most active period of synapse elimination during brain development. LTD is also directly associated with shrinkage and loss of dendritic spines in live-imaging experiments [33,34], leading many to think about NMDA receptor-dependent LTD as an electrophysiological correlate (or harbinger) of excitatory synapse elimination. Given that apoptosis mechanisms seem to underlie LTD (as discussed above), it is appealing to consider LTD and the associated spine shrinkage and elimination as different facets of an overall process of synapse involution.



**Figure 2.** Relative size and distribution of mitochondria and spines in neuronal dendrites. Dendrites of cultured hippocampal neurons days *in vitro* (DIV) are shown with mitochondria labelled with mitochondria-targeted red fluorescence protein (RFP; red) (a), and in merge with dendritic spines labelled with yellow fluorescence protein (YFP)-actin (green) (b). Dendritic mitochondria range in length from 1–2  $\mu\text{m}$  to 20–30  $\mu\text{m}$ . In most cases, a single mitochondrion spans a distance that encompasses multiple dendritic spines.

What are the molecular mechanisms that underlie spine shrinkage and synapse loss associated with LTD? In programmed cell death, caspase-3 and other effector caspases orchestrate dismantling of the cell structure through cleavage of specific substrates [35]. It seems reasonable to suppose that localized synaptic apoptosis, such as in LTD, might also involve local cleavage of key substrates by caspase-3, leading to local pruning of neuronal structures. Actin rearrangements underlie the structural remodelling of dendritic spines, while microtubules are the core support of dendritic shafts [36]. Various actin regulatory proteins, including ROCK1, gelsolin, spectrin and fodrin are present in dendrites [37–39] and are known caspase-3 targets [40–42]. Microtubules play an essential role in shaping the dendritic tree. Tau, a microtubule-associated protein, is also a caspase-3 target [43]. It is worth pointing out here that caspase-3 activation has also been observed not just downstream of NMDA receptor activation, but dependent on NMDA-induced AMPA receptor internalization [44].

Other prominent signalling molecules that are involved in LTD and shown to be present in dendrites are the calcium-sensitive phosphatase calcineurin and the protein kinase Akt. Calcineurin regulates ion channels and cytoskeletal proteins [45,46], inhibits synaptic function [47] and is proteolytically activated by caspase-3 [48]. Akt is an antiapoptotic and pro-growth kinase that phosphorylates and inhibits glycogen synthase kinase (GSK) 3 $\beta$  activity, which is required for induction of LTD [49,50]. Akt is also a substrate of caspase-3 [51], and prevention of cleavage of Akt blocks LTD [23] (figure 1). Hence,

caspase-3 involvement in LTD induction could involve Akt proteolysis, which would in turn increase GSK3 $\beta$  activity. It is interesting that Akt is a proto-oncogene that promotes dendrite growth [52], raising the possibility that the phosphatidylinositol 3 (PI3) kinase-Akt signalling pathway is antagonistic to the mitochondrial apoptosis-caspase-3 pathway in the local regulation of synapse strength and synapse morphology.

The postsynaptic density (PSD) is a *sine qua non* feature of excitatory synapses; it is tightly aligned with the presynaptic active zone and typically found at the tip of dendritic spines. A complex, proteinaceous, membrane-associated organelle, the PSD is the structure in which postsynaptic glutamate receptors are concentrated and where they interact physically and functionally with scaffold proteins and associated signalling molecules (kinases, phosphatases, guanine nucleotide exchange factors, GTPase activating proteins, etc.) [53]. The size of the PSD (and of the dendritic spine) correlates closely with the strength of the synapse and the abundance of postsynaptic AMPA receptors [53]. Therefore, during LTD, the removal of postsynaptic AMPA receptors and associated shrinkage of synapses and spines must involve major molecular rearrangements, and ultimately down-sizing, of the PSD. Indeed, a recent study by Granger *et al.* supports the notion that structural reorganization of the synapse is a fundamental mechanism underlying synaptic plasticity [54,55].

The PSD is organized around a lattice of key scaffold proteins, of which PSD-95 is one of the most abundant and best understood [56,57]. PSD-95 overexpression boosts excitatory synaptic transmission, a function that depends on the accumulation of PSD-95 in synapses, which in turn is regulated by phosphorylation of PSD-95 on ser-295 by protein kinase JNK [58]. Ser-295 dephosphorylation of PSD-95 occurs rapidly following LTD-like stimulation and is required for AMPA receptor internalization and LTD [58]. The dephosphorylation appears to be mediated by PP1/PP2A phosphatases, which are activated during LTD [46,59]. Dephosphorylation of ser-295—as well as phosphorylation of threonine-17 by GSK-3—contributes to the destabilization of PSD-95 in the PSD [60], which should lead to mobilization and loss of PSD-95 from synapses and mediate morphological shrinkage of synapses/spines in addition to weakening of synaptic transmission.

It is likely that the size and structure of the PSD are also regulated by additional mechanisms during LTD, such as protein degradation by proteases and by proteasomes, which are recruited to spines in activity-dependent fashion [61,62]. Whether caspase-3 substrates exist in the PSD is presently unknown and an exciting question to pursue in future studies.

## 5. External forces in elimination of spines and synapses: microglia engulfment

In addition to caspase activation, removal of apoptotic cellular debris by phagocytic cells is a core event in programmed cell death [63]. As LTD and synapse involution by local apoptosis could depend on similar mechanisms of programmed cell death, one is forced to wonder whether phagocytosis might play a role in removal of ‘dying’ synapses.

Indeed, recent studies point to phagocytic processes for clearance of synapses and spines in the nervous system [64,65]. Microglia (resident macrophage-like cells of the central nervous system) have been shown in imaging studies to engulf remnants of synapses in the developing brain [66]. The phagocytosis of

synapses appears to depend, at least in part, on complement proteins, which have been long studied in innate immunity and which are significantly expressed in the brain. A major function of complement is to tag microbes or unwanted cells and cellular debris for rapid clearance by macrophage engulfment or complement-mediated cell lysis [67]. Complement cascade components C1q and C3 can be found at synapses during the period of synapse elimination and are required for the developmental pruning of retinogeniculate synapses [65,68]. Disruption of microglia or complement function caused defects in the development of neural circuits [65–69].

These studies suggest that synapse elimination in development and in disease might involve recognition and clearance of dying synapses by professional phagocytic cells, analogous to the removal of apoptotic cell corpses in programmed cell death.

## 6. How is the mitochondrial apoptosis pathway activated by long-term depression stimuli?

Mitochondria are organelles well positioned to play a role in synaptic plasticity. Mitochondria are present close to and occasionally even within individual spines (figure 2), and their distribution and motility are regulated by synaptic activity [70].

Well known to act as Ca<sup>2+</sup> buffers in cells, mitochondria take up Ca<sup>2+</sup> after synaptic stimulation [71]. Additionally, Ca<sup>2+</sup> uptake by mitochondria promotes their release of pro-apoptotic factors [72]. Thus, a dendritic mitochondrion can act as a sensor of prolonged, moderate elevation of postsynaptic Ca<sup>2+</sup>, a condition that seems to be critical for induction of LTD.

Mitochondria also often have close contacts with the endoplasmic reticulum (ER) [73], which is extensively present in postsynaptic compartments (figure 1). Activation of mitochondrial Ca<sup>2+</sup> uptake by Ca<sup>2+</sup> release from ER leads to Ca<sup>2+</sup> accumulation in mitochondria [74] and cytochrome *c* release [75]. Ca<sup>2+</sup> release from ER stores via ryanodine receptors and IP3 receptors may also play a role in LTD in hippocampal neurons and Purkinje cells [28,76,77], and appears to be required for caspase-9/3 activation by NMDA stimulation in neurons [23]. It is tempting to speculate that the functional interaction of ER and mitochondria—which has been recently shown to also be involved in autophagosome formation [78]—might be important for LTD induction.

## 7. Long-term depression in neurodegeneration

Synapse loss and reduced dendritic spine density are characteristic features of various neurodegenerative diseases [68,79,80]. NMDA receptor activity has been implicated in the neurotoxicity of epilepsy, Huntington’s disease, Alzheimer’s disease, stroke and traumatic brain injury [81–85]. Excessive NMDA receptor activation can induce loss of dendritic spines and neurite beading [86], and subsequent neuronal death [87]. Hence, it is possible that physiological LTD and synapse loss in neurodegeneration share common mechanisms. In line with this hypothesis, A $\beta$  oligomers (which are probable pathogenic agents in Alzheimer’s disease) can enhance LTD. A $\beta$  oligomers can also induce or promote spine loss, AMPA receptor internalization, stimulation of calcineurin and GSK3 $\beta$  and activation of caspase-3 [88–95], which are common to the features of NMDA receptor-dependent LTD. Notably, D’Amelio *et al.* [47] observed that active caspase-3 is elevated in the dendritic spines of a

transgenic mouse model of Alzheimer's disease (Tg2576), in the absence of cell death, and this caspase-3 activation correlated with memory impairment and reduced spine density and size.

## 8. Are there similar apoptotic mechanisms occurring in axons and presynaptic sites?

Most of the studies reviewed here have focused on dendrites and spines, because the postsynaptic compartment is easier to manipulate and measure experimentally in molecular-genetic and electrophysiological experiments. Nevertheless, there have been a few studies showing the involvement of caspases in axon pruning in the absence of neuronal death [96,97]. Although further studies are needed, it appears that apoptotic mechanisms can also regulate axonal morphology. It will be interesting to investigate whether local activation of caspases can locally affect synapse structure and function from the presynaptic side [98,99].

## 9. Viewing long-term potentiation and long-term depression as growth versus apoptosis of synapses

At a very simple cell biological level, we propose that LTD and synapse loss are the opposites of LTP and synapse formation: LTD and synapse elimination can be regarded as manifestations of synapse 'involution', whereas LTP and new synapse formation can be considered synapse 'growth'. Both are, of

course, natural, even temporally overlapping processes in the maturation of neurons and circuits.

In the context of growth versus involution, it is notable that LTP and LTD use largely opposing signalling pathways that have been much studied in the context of oncogenesis. In contrast to the attrition of synapses in LTD, which is dependent on apoptotic signalling pathways (as discussed above), LTP relies on signalling mechanisms implicated in cell growth and proliferation. For example, activation of the proto-oncogene Ras, and its oncogenic downstream kinases PI3 kinase and ERK, favours LTP rather than LTD [100,101]. The proto-oncogene Akt, which is downstream of PI3 kinase, promotes the growth of dendrites and LTP but antagonizes LTD [49]. Phosphatase and tensin homolog (PTEN), a protein phosphatase and tumour suppressor that opposes the action of the Ras-PI3 kinase pathway, drives synaptic depression and is required for LTD [102]. The protein kinase GSK3 $\beta$  is critical for NMDA receptor-dependent LTD [49] and is also known to promote cell death, at least in part via the intrinsic apoptosis pathway [103].

In conclusion, recent data from a variety of experimental systems point to an important role for apoptotic mechanisms in LTD and synapse elimination. By analogy to cancer signalling, we suggest that common molecular mechanisms that drive cell growth and proliferation in mitotic cells are used in postmitotic neurons for expansion and strengthening of specific synapses (LTP). Conversely, postmitotic neurons have adapted the molecular mechanisms of programmed cell death to weaken and eliminate unwanted synaptic connections in localized regions of the cell.

## References

- Malenka RC, Bear MF. 2004 LTP and LTD: an embarrassment of riches. *Neuron* **44**, 5–21. (doi:10.1016/j.neuron.2004.09.012)
- Collingridge GL, Peineau S, Howland JG, Wang YT. 2010 Long-term depression in the CNS. *Nat. Rev. Neurosci.* **11**, 459–473. (doi:10.1038/nrn2867)
- Bliss TV, Collingridge GL. 1993 A synaptic model of memory: long-term potentiation in the hippocampus. *Nature* **361**, 31–39. (doi:10.1038/361031a0)
- Kerchner GA, Nicoll RA. 2008 Silent synapses and the emergence of a postsynaptic mechanism for LTP. *Nat. Rev. Neurosci.* **9**, 813–825. (doi:10.1038/nrn2501)
- Bear MF. 2003 Bidirectional synaptic plasticity: from theory to reality. *Phil. Trans. R. Soc. Lond. B* **358**, 649–655. (doi:10.1098/rsth.2002.1255)
- Thomas GM, Huganir RL. 2004 MAPK cascade signalling and synaptic plasticity. *Nat. Rev. Neurosci.* **5**, 173–183. (doi:10.1038/nrn1346)
- Shepherd JD, Huganir RL. 2007 The cell biology of synaptic plasticity: AMPA receptor trafficking. *Annu. Rev. Cell Dev. Biol.* **23**, 613–643. (doi:10.1146/annurev.cellbio.23.090506.123516)
- Collingridge GL, Isaac JT, Wang YT. 2004 Receptor trafficking and synaptic plasticity. *Nat. Rev. Neurosci.* **5**, 952–962. (doi:10.1038/nrn1556)
- Malinow R, Malenka RC. 2002 AMPA receptor trafficking and synaptic plasticity. *Annu. Rev. Neurosci.* **25**, 103–126. (doi:10.1146/annurev.neuro.25.112701.142758)
- Kerr JF, Wyllie AH, Currie AR. 1972 Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* **26**, 239–257. (doi:10.1038/bjc.1972.33)
- Fuchs Y, Steller H. 2011 Programmed cell death in animal development and disease. *Cell* **147**, 742–758. (doi:10.1016/j.cell.2011.10.033)
- Kim WR, Sun W. 2011 Programmed cell death during postnatal development of the rodent nervous system. *Dev. Growth Differ.* **53**, 225–235. (doi:10.1111/j.1440-169X.2010.01226.x)
- Kuo CT, Zhu S, Younger S, Jan LY, Jan YN. 2006 Identification of E2/E3 ubiquitinating enzymes and caspase activity regulating *Drosophila* sensory neuron dendrite pruning. *Neuron* **51**, 283–290. (doi:10.1016/j.neuron.2006.07.014)
- Williams DW, Kondo S, Krzyzanowska A, Hiromi Y, Truman JW. 2006 Local caspase activity directs engulfment of dendrites during pruning. *Nat. Neurosci.* **9**, 1234–1236. (doi:10.1038/nn1774)
- Gilman CP, Mattson MP. 2002 Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? *Neuromolecular Med.* **2**, 197–214. (doi:10.1385/MMM.2:2:197)
- Campbell DS, Holt CE. 2003 Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. *Neuron* **37**, 939–952. (doi:10.1016/S0896-6273(03)00158-2)
- Huesmann GR, Clayton DF. 2006 Dynamic role of postsynaptic caspase-3 and BIRC4 in zebra finch song-response habituation. *Neuron* **52**, 1061–1072. (doi:10.1016/j.neuron.2006.10.033)
- Hyman BT, Yuan J. 2012 Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. *Nat. Rev. Neurosci.* **13**, 395–406. (doi:10.1038/nrn3228)
- Tait SW, Green DR. 2010 Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* **11**, 621–632. (doi:10.1038/nrm2952)
- Youle RJ, Strasser A. 2008 The BCL-2 protein family: opposing activities that mediate cell death. *Nat. Rev. Mol. Cell Biol.* **9**, 47–59. (doi:10.1038/nrn2308)
- Srinivasula SM, Ashwell JD. 2008 IAPs: what's in a name? *Mol. Cell* **30**, 123–135. (doi:10.1016/j.molcel.2008.03.008)
- Riedl SJ, Shi Y. 2004 Molecular mechanisms of caspase regulation during apoptosis. *Nat. Rev. Mol. Cell Biol.* **5**, 897–907. (doi:10.1038/nrn1496)
- Li Z *et al.* 2010 Caspase-3 activation via mitochondria is required for long-term depression

- and AMPA receptor internalization. *Cell* **141**, 859–871. (doi:10.1016/j.cell.2010.03.053)
24. Jiao S, Li Z. 2011 Nonapoptotic function of BAD and BAX in long-term depression of synaptic transmission. *Neuron* **70**, 758–772. (doi:10.1016/j.neuron.2011.04.004)
  25. Mattson MP, Keller JN, Begley JG. 1998 Evidence for synaptic apoptosis. *Exp. Neurol.* **153**, 35–48. (doi:10.1006/exnr.1998.6863)
  26. Lu C, Fu W, Salvesen GS, Mattson MP. 2002 Direct cleavage of AMPA receptor subunit GluR1 and suppression of AMPA currents by caspase-3: implications for synaptic plasticity and excitotoxic neuronal death. *Neuromolecular Med.* **1**, 69–79. (doi:10.1385/NMM:1:1:69)
  27. Rintoul GL, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ. 2003 Glutamate decreases mitochondrial size and movement in primary forebrain neurons. *J. Neurosci.* **23**, 7881–7888.
  28. Nishiyama M, Hong K, Mikoshiba K, Poo MM, Kato K. 2000 Calcium stores regulate the polarity and input specificity of synaptic modification. *Nature* **408**, 584–588. (doi:10.1038/35046067)
  29. Scanziani M, Nicoll RA, Malenka RC. 1996 Heterosynaptic long-term depression in the hippocampus. *J. Physiol. Paris* **90**, 165–166. (doi:10.1016/S0928-4257(97)81416-7)
  30. Christie BR, Stellwagen D, Abraham WC. 1995 Evidence for common expression mechanisms underlying heterosynaptic and associative long-term depression in the dentate gyrus. *J. Neurophysiol.* **74**, 1244–1247.
  31. Kemp N, McQueen J, Faulkes S, Bashir ZI. 2000 Different forms of LTD in the CA1 region of the hippocampus: role of age and stimulus protocol. *Eur. J. Neurosci.* **12**, 360–366. (doi:10.1046/j.1460-9568.2000.00903.x)
  32. Wagner JJ, Alger BE. 1995 GABAergic and developmental influences on homosynaptic LTD and depotentiation in rat hippocampus. *J. Neurosci.* **15**, 1577–1586.
  33. Oh WC, Hill TC, Zito K. 2013 Synapse-specific and size-dependent mechanisms of spine structural plasticity accompanying synaptic weakening. *Proc. Natl Acad. Sci. USA* **110**, E305–E312. (doi:10.1073/pnas.1214705110)
  34. Zhou Q, Homma KJ, Poo MM. 2004 Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. *Neuron* **44**, 749–757. (doi:10.1016/j.neuron.2004.11.011)
  35. Crawford ED, Wells JA. 2011 Caspase substrates and cellular remodeling. *Annu. Rev. Biochem.* **80**, 1055–1087. (doi:10.1146/annurev-biochem-061809-121639)
  36. Hotulainen P, Hoogenraad CC. 2010 Actin in dendritic spines: connecting dynamics to function. *J. Cell Biol.* **189**, 619–629. (doi:10.1083/jcb.201003008)
  37. Salminen A, Suuronen T, Kaariranta K. 2008 ROCK, PAK, and Toll of synapses in Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **371**, 587–590. (doi:10.1016/j.bbrc.2008.04.148)
  38. Furukawa K, Fu W, Li Y, Witke W, Kwiatkowski DJ, Mattson MP. 1997 The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. *J. Neurosci.* **17**, 8178–8186.
  39. Ursitti JA *et al.* 2001 Spectrins in developing rat hippocampal cells. *Brain Res. Dev. Brain Res.* **129**, 81–93. (doi:10.1016/S0165-3806(01)00160-2)
  40. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. 2001 Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. *Nat. Cell Biol.* **3**, 346–352. (doi:10.1038/35070019)
  41. Kothakota S *et al.* 1997 Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. *Science* **278**, 294–298. (doi:10.1126/science.278.5336.294)
  42. Wang KK, Posmantur R, Nath R, McGinnis K, Whitton M, Talanian RV, Glantz SB, Morrow JS. 1998 Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. *J. Biol. Chem.* **273**, 22 490–22 497. (doi:10.1074/jbc.273.35.22490)
  43. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M, Cattaneo A. 2000 The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. *J. Neurochem.* **75**, 624–633. (doi:10.1046/j.1471-4159.2000.0750624.x)
  44. Wang Y, Ju W, Liu L, Fam S, D'Souza S, Taghibiglou C, Salter M, Wang YT. 2004  $\alpha$ -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPA) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis. *J. Biol. Chem.* **279**, 41 267–41 270. (doi:10.1074/jbc.C400199200)
  45. Halpain S, Hipolito A, Saffer L. 1998 Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. *J. Neurosci.* **18**, 9835–9844.
  46. Winder DG, Sweatt JD. 2001 Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. *Nat. Rev. Neurosci.* **2**, 461–474. (doi:10.1038/35081514)
  47. D'Amelio M *et al.* 2011 Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. *Nat. Neurosci.* **14**, 69–76. (doi:10.1038/nn.2709)
  48. Mukerjee N, McGinnis KM, Park YH, Gnegy ME, Wang KK. 2000 Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. *Arch. Biochem. Biophys.* **379**, 337–343. (doi:10.1006/abbi.2000.1889)
  49. Peineau S *et al.* 2007 LTP inhibits LTD in the hippocampus via regulation of GSK3 $\beta$ . *Neuron* **53**, 703–717. (doi:10.1016/j.neuron.2007.01.029)
  50. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL. 2008 The role of GSK-3 in synaptic plasticity. *Br. J. Pharmacol.* **153**(Suppl. 1), S428–S437. (doi:10.1038/bjp.2008.2)
  51. Asselin E, Mills GB, Tsang BK. 2001 XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. *Cancer Res.* **61**, 1862–1868.
  52. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. 2005 Control of dendritic arborization by the phosphoinositide-3-kinase-Akt-mammalian target of rapamycin pathway. *J. Neurosci.* **25**, 11 300–11 312. (doi:10.1523/JNEUROSCI.2270-05.2005)
  53. Sheng M, Kim E. 2011 The postsynaptic organization of synapses. *Cold Spring Harbor Perspect. Biol.* **3**, a005678. (doi:10.1101/cshperspect.a005678)
  54. Granger AJ, Shi Y, Lu W, Cerpas M, Nicoll RA. 2013 LTP requires a reserve pool of glutamate receptors independent of subunit type. *Nature* **493**, 495–500. (doi:10.1038/nature11775)
  55. Sheng M, Malinow R, Hugarir R. 2013 Neuroscience: strength in numbers. *Nature* **493**, 482–483. (doi:10.1038/493482a)
  56. Kim E, Sheng M. 2004 PDZ domain proteins of synapses. *Nat. Rev. Neurosci.* **5**, 771–781. (doi:10.1038/nrn1517)
  57. Sheng M, Hoogenraad CC. 2007 The postsynaptic architecture of excitatory synapses: a more quantitative view. *Annu. Rev. Biochem.* **76**, 823–847. (doi:10.1146/annurev.biochem.76.060805.160029)
  58. Kim MJ, Futai K, Jo J, Hayashi Y, Cho K, Sheng M. 2007 Synaptic accumulation of PSD-95 and synaptic function regulated by phosphorylation of serine-295 of PSD-95. *Neuron* **56**, 488–502. (doi:10.1016/j.neuron.2007.09.007)
  59. Mulkey RM, Herron CE, Malenka RC. 1993 An essential role for protein phosphatases in hippocampal long-term depression. *Science* **261**, 1051–1055. (doi:10.1126/science.8394601)
  60. Nelson C *et al.* 2013 Phosphorylation of threonine-19 of PSD-95 by GSK-3 $\beta$  is required for PSD-95 mobilization and long-term depression. *J. Neurosci.* **33**, 12 122–12 135. (doi:10.1523/JNEUROSCI.0131-13.2013)
  61. Bingol B, Sheng M. 2011 Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. *Neuron* **69**, 22–32. (doi:10.1016/j.neuron.2010.11.006)
  62. Bingol B, Wang CF, Amott D, Cheng D, Peng J, Sheng M. 2010 Autophosphorylated CaMKII $\alpha$  acts as a scaffold to recruit proteasomes to dendritic spines. *Cell* **140**, 567–578. (doi:10.1016/j.cell.2010.01.024)
  63. Fadok VA, Chimini G. 2001 The phagocytosis of apoptotic cells. *Semin. Immunol.* **13**, 365–372. (doi:10.1006/smim.2001.0333)
  64. Aguzzi A, Barres BA, Bennett ML. 2013 Microglia: scapegoat, saboteur, or something else? *Science* **339**, 156–161. (doi:10.1126/science.1227901)
  65. Stephan AH, Barres BA, Stevens B. 2012 The complement system: an unexpected role in synaptic pruning during development and disease. *Annu. Rev. Neurosci.* **35**, 369–339. (doi:10.1146/annurev-neuro-061010-113810)
  66. Schafer DP *et al.* 2012 Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* **74**, 691–705. (doi:10.1016/j.neuron.2012.03.026)
  67. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010 Complement: a key system for immune surveillance and homeostasis. *Nat. Immunol.* **11**, 785–797. (doi:10.1038/ni.1923)

68. Stevens B *et al.* 2007 The classical complement cascade mediates CNS synapse elimination. *Cell* **131**, 1164–1178. (doi:10.1016/j.cell.2007.10.036)
69. Paolicelli RC *et al.* 2011 Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458. (doi:10.1126/science.1202529)
70. Sheng ZH, Cai Q. 2012 Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. *Nat. Rev. Neurosci.* **13**, 77–93. (doi:10.1038/nrg3141)
71. Pivovarova NB, Pozzo-Miller LD, Hongpaisan J, Andrews SB. 2002 Correlated calcium uptake and release by mitochondria and endoplasmic reticulum of CA3 hippocampal dendrites after afferent synaptic stimulation. *J. Neurosci.* **22**, 10 653–10 661.
72. Pacher P, Hajnoczky G. 2001 Propagation of the apoptotic signal by mitochondrial waves. *Embo J.* **20**, 4107–4121. (doi:10.1093/emboj/20.15.4107)
73. Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T. 1998 Close contacts with the endoplasmic reticulum as determinants of mitochondrial  $Ca^{2+}$  responses. *Science* **280**, 1763–1766. (doi:10.1126/science.280.5370.1763)
74. Csordas G, Thomas AP, Hajnoczky G. 1999 Quasi-synaptic calcium signal transmission between endoplasmic reticulum and mitochondria. *Embo J.* **18**, 96–108. (doi:10.1093/emboj/18.1.96)
75. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. 2002 Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial  $Ca^{2+}$  stores. *J. Biol. Chem.* **277**, 9219–9225. (doi:10.1074/jbc.M106817200)
76. Kohda K, Inoue T, Mikoshiba K. 1995  $Ca^{2+}$  release from  $Ca^{2+}$  stores, particularly from ryanodine-sensitive  $Ca^{2+}$  stores, is required for the induction of LTD in cultured cerebellar Purkinje cells. *J. Neurophysiol.* **74**, 2184–2188.
77. Reyes M, Stanton PK. 1996 Induction of hippocampal long-term depression requires release of  $Ca^{2+}$  from separate presynaptic and postsynaptic intracellular stores. *J. Neurosci.* **16**, 5951–5960.
78. Hamasaki M *et al.* 2013 Autophagosomes form at ER-mitochondria contact sites. *Nature* **495**, 389–393. (doi:10.1038/nature11910)
79. Selkoe DJ. 2002 Alzheimer's disease is a synaptic failure. *Science* **298**, 789–791. (doi:10.1126/science.1074069)
80. Luo L, O'Leary DD. 2005 Axon retraction and degeneration in development and disease. *Annu. Rev. Neurosci.* **28**, 127–156. (doi:10.1146/annurev.neuro.28.061604.135632)
81. Urban L, Aitken PG, Friedman A, Somjen GG. 1990 An NMDA-mediated component of excitatory synaptic input to dentate granule cells in 'epileptic' human hippocampus studied in vitro. *Brain Res.* **515**, 319–322. (doi:10.1016/0006-8993(90)90615-1)
82. Milnerwood AJ *et al.* 2010 Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. *Neuron* **65**, 178–190. (doi:10.1016/j.neuron.2010.01.008)
83. Sonkusare SK, Kaul CL, Ramarao P. 2005 Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope. *Pharmacol. Res.* **51**, 1–17. (doi:10.1016/j.phrs.2004.05.005)
84. Faden AI, Demediuk P, Panter SS, Vink R. 1989 The role of excitatory amino acids and NMDA receptors in traumatic brain injury. *Science* **244**, 798–800. (doi:10.1126/science.2567056)
85. Choi DW, Rothman SM. 1990 The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. *Annu. Rev. Neurosci.* **13**, 171–182. (doi:10.1146/annurev.ne.13.030190.001131)
86. Isokawa M, Levesque MF. 1991 Increased NMDA responses and dendritic degeneration in human epileptic hippocampal neurons in slices. *Neurosci. Lett.* **132**, 212–216. (doi:10.1016/0304-3940(91)90304-C)
87. Hu NW, Ondrejcek T, Rowan MJ. 2012 Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. *Pharmacol. Biochem. Behav.* **100**, 855–862. (doi:10.1016/j.pbb.2011.04.013)
88. Harada J, Sugimoto M. 1999 Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. *Brain Res.* **842**, 311–323. (doi:10.1016/S0006-8993(99)01808-9)
89. Jo J *et al.* 2011  $A\beta(1-42)$  inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3 $\beta$ . *Nat. Neurosci.* **14**, 545–547. (doi:10.1038/nn.2785)
90. Shankar GM *et al.* 2008 Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* **14**, 837–842. (doi:10.1038/nm1782)
91. Knobloch M, Mansuy IM. 2008 Dendritic spine loss and synaptic alterations in Alzheimer's disease. *Mol. Neurobiol.* **37**, 73–82. (doi:10.1007/s12035-008-8018-z)
92. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. 2006 AMPAR removal underlies  $A\beta$ -induced synaptic depression and dendritic spine loss. *Neuron* **52**, 831–843. (doi:10.1016/j.neuron.2006.10.035)
93. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007 Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J. Neurosci.* **27**, 2866–2875. (doi:10.1523/JNEUROSCI.4970-06.2007)
94. Snyder EM *et al.* 2005 Regulation of NMDA receptor trafficking by amyloid-beta. *Nat. Neurosci.* **8**, 1051–1058. (doi:10.1038/nn1503)
95. Olsen KM, Sheng M. 2012 NMDA receptors and BAX are essential for Abeta impairment of LTP. *Sci. Rep.* **2**, 225. (doi:10.1038/srep00225)
96. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. 2009 APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* **457**, 981–989. (doi:10.1038/nature07767)
97. Simon DJ *et al.* 2012 A caspase cascade regulating developmental axon degeneration. *J. Neurosci.* **32**, 17 540–17 553. (doi:10.1523/JNEUROSCI.3012-12.2012)
98. Hickman JA, Hardwick JM, Kaczmarek LK, Jonas EA. 2008 Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. *J. Neurophysiol.* **99**, 1515–1522. (doi:10.1152/jn.00598.2007)
99. Li H *et al.* 2008 Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. *Proc. Natl Acad. Sci. USA* **105**, 2169–2174. (doi:10.1073/pnas.0711647105)
100. Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. 2002 Ras and Rap control AMPA receptor trafficking during synaptic plasticity. *Cell* **110**, 443–455. (doi:10.1016/S0092-8674(02)00897-8)
101. Qin Y *et al.* 2005 State-dependent Ras signaling and AMPA receptor trafficking. *Genes Dev.* **19**, 2000–2015. (doi:10.1101/gad.342205)
102. Jurado S, Benoist M, Lario A, Knafo S, Petrok CN, Esteban JA. 2010 PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. *EMBO J.* **29**, 2827–2840. (doi:10.1038/emboj.2010.160)
103. Beurel E, Jope RS. 2006 The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. *Progr. Neurobiol.* **79**, 173–189. (doi:10.1016/j.pneurobio.2006.07.006)